Bill Sponsor
House Bill 3396
116th Congress(2019-2020)
Functional Gastrointestinal and Motility Disorders Research Enhancement Act of 2019
Introduced
Introduced
Introduced in House on Jun 20, 2019
Overview
Text
Introduced
Jun 20, 2019
Latest Action
Jun 21, 2019
Origin Chamber
House
Type
Bill
Bill
The primary form of legislative measure used to propose law. Depending on the chamber of origin, bills begin with a designation of either H.R. or S. Joint resolution is another form of legislative measure used to propose law.
Bill Number
3396
Congress
116
Policy Area
Health
Health
Primary focus of measure is science or practice of the diagnosis, treatment, and prevention of disease; health services administration and funding, including such programs as Medicare and Medicaid; health personnel and medical education; drug use and safety; health care coverage and insurance; health facilities. Measures concerning controlled substances and drug trafficking may fall under Crime and Law Enforcement policy area.
Sponsorship by Party
Republican
Wisconsin
Republican
Arizona
Democrat
California
Democrat
California
Democrat
Colorado
Democrat
District of Columbia
Democrat
Massachusetts
Democrat
Nevada
Republican
New Jersey
Democrat
New York
Democrat
New York
Democrat
North Carolina
Democrat
North Carolina
Republican
Pennsylvania
Democrat
Wisconsin
Democrat
Wisconsin
Democrat
Wisconsin
House Votes (0)
Senate Votes (0)
No House votes have been held for this bill.
Summary

Functional Gastrointestinal and Motility Disorders Research Enhancement Act of 2019

This bill allows the National Institutes of Health to expand, intensify, and coordinate its activities with respect to functional gastrointestinal and motility disorders (FGIMDs), including by

  • expanding basic and clinical research into FGIMDs by implementing the research recommendations of the National Commission on Digestive Diseases,
  • providing support for the establishment of centers of excellence on FGIMDs,
  • supporting innovative approaches to educating health care providers and patients regarding strategies that improve patient-provider relationships and care,
  • directing the National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK) to provide the necessary funding for the continued expansion and advancement of the FGIMDs research portfolio, and
  • directing NIDDK and the Eunice Kennedy Shriver National Institute of Child Health and Human Development to expand research into FGIMDs that impact children.

The Department of Health and Human Services may engage in public awareness and education activities to increase understanding and recognition of FGIMDs.

Text (1)
June 20, 2019
Actions (3)
06/21/2019
Referred to the Subcommittee on Health.
06/20/2019
Referred to the House Committee on Energy and Commerce.
06/20/2019
Introduced in House
Public Record
Record Updated
Nov 1, 2022 1:50:59 PM